Site icon OncologyTube

Combination Trials with New IO Agents: How Can we Define the Best Treatment with Current Data?

Bernard Escudier, Gustave Roussy, Villejuif, France asks teh question “Combination Trials with New IO Agents: How Can we Define the Best Treatment with Current Data?” at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Exit mobile version